

AMICUS THERAPEUTICS INC  
 Form 4  
 June 07, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Weinhoff Gregory M

2. Issuer Name and Ticker or Trading Symbol  
 AMICUS THERAPEUTICS INC  
 [FOLD]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 C/O CHL MEDICAL  
 PARTNERS, 1055 WASHINGTON  
 BLVD.

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 06/05/2007

Director  10% Owner  
 Officer (give title below)  Other (specify below)

(Street)  
 STAMFORD, CT 06901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2007		C		1,975,223	A	11
					2,108,555	I	

By  
 Partnership  
(4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
 (9-02)

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount Number Shares
Series A Convertible Preferred Stock	(1)	06/05/2007		C	83,278	04/15/2002 (1)	Common Stock 83,278
Series A Convertible Preferred Stock	(1)	06/05/2007		C	5,611	04/15/2002 (1)	Common Stock 5,611
Series B Convertible Preferred Stock	(1)	06/05/2007		C	734,803	05/04/2004 (1)	Common Stock 734,803
Series B Convertible Preferred Stock	(1)	06/05/2007		C	49,509	05/04/2004 (1)	Common Stock 49,509
Series B Convertible Preferred Stock	(1)	06/05/2007		C	11,182	04/18/2006 (1)	Common Stock 11,182
Series B Convertible Preferred Stock	(1)	06/05/2007		C	753	04/18/2006 (1)	Common Stock 753
Series C Convertible Preferred	(1)	06/05/2007		C	247,850	08/16/2005 (1)	Common Stock 247,850

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Stock

Series C Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	16,669	08/16/2005	<u>(1)</u>	Common Stock	16,699
Series C Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	247,850	04/17/2006	<u>(1)</u>	Common Stock	247,850
Series C Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	16,669	04/17/2006	<u>(1)</u>	Common Stock	16,699
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	96,233	09/13/2006	<u>(1)</u>	Common Stock	96,233
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	6,484	09/13/2006	<u>(1)</u>	Common Stock	6,484
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	96,223	03/09/2007	<u>(1)</u>	Common Stock	96,233
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	6,484	03/09/2007	<u>(1)</u>	Common Stock	6,484
Series A Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	333,111	07/15/2002	<u>(1)</u>	Common Stock	333,111

Series A  
Convertible  
Preferred  
Stock

(1)

06/05/2007

C

22,444

07/15/2002

(1)

Common  
Stock

22,444

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Weinhoff Gregory M C/O CHL MEDICAL PARTNERS 1055 WASHINGTON BLVD. STAMFORD, CT 06901		X		

## Signatures

/s/ Gregory M.  
Weinhoff

06/06/2007

\*\*Signature of Reporting  
Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each of the Series A Convertible Preferred Stock, the Series B Convertible Preferred Stock, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock automatically converted into Amicus Therapeutics, Inc. common stock on a one-for-one basis upon the closing of Amicus Therapeutics, Inc.'s initial public offering on June 5, 2007

(2) The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

(3) The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

(4) Consists of 1,975,456 shares held by CHL Medical Partner II, L.P. and 133,099 shares held by CHL Medical Partners II Side Fund, L.P. The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.